CliffBio
biologic

Corifact

Factor XIII Concentrate (Human)

Loss of exclusivityFebruary 2023projected — 12-year biologic exclusivity estimate
CompanyCSL Behring →See this company's full patent-cliff portfolio

Drug detail

Brand nameCorifact
Active ingredientFactor XIII Concentrate (Human)
Strength1000-1600IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalFebruary 2011
Marketing statusRx

More from CSL Behring

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Corifact patent cliff — loss of exclusivity February 2023 | CliffBio